![](bg5.png)
cells at the beginning of scleroderma. In the
following, fibrosis tissue induces perfusion defect
and becomes the main cause of hypoxia (Van Hal et
al, 2011). Since bleomycin-induced model better
represents tissue fibrotic changes (Yamamoto et al,
2011), we suppose that statistically significant
magnification in porphyrin fluorescence rate on the
21
st
day indicates a chronic hypoxia and is based on
the perfusion defect.
We also assumed the development of
inflammation of the dermis during fibrosis formation
in experimental model. High levels of blood serum
C-reactive protein in BLM group on the 7th day
were determined in support of it. That implies the
disease high activity and is a significant predictor of
complications and premature mortality (Muangchan
et al., 2012; Darby et al., 2016). Hence, daily
subcutaneous injections also were associated with
inflammation under panniculus carnosus in both
animal groups. Probably, the increase in porphyrin
fluorescence intensity in both groups was due to it.
Nevertheless, to prove our assumption a separate
study needs to be carried out providing with the
method development that will make it possible to
distinguish chronic hypoxia and inflammation of
different sites.
4 CONCLUSIONS
The use of optical technologies in the experiment
enabled to determine the increment in endogenous
fluorescence intensity of collagen and the decrease
in tissue oxygen intake in the fibrosis area. We also
registered the increase in endogenous fluorescence
intensity rate of the porphyrins as a potential chronic
hypoxia and inflammatory marker.
It is important that all optical methods used in
this study were non-invasive. Nevertheless we
managed to obtain quantitative and impersonal
information. Considering the fact that the animal
scleroderma model is relevant, the data obtained can
be reproduced in man.
The results of the experiment, of course,
demonstrate the necessity of a research continuation
in this direction, but already now it is possible to
predict great opportunities for optical technologies
in the diagnosis of skin fibrosis.
REFERENCES
Avouac, J., 2014. Mouse Model of Experimental Dermal
Fibrosis: The Bleomycin-Induced Dermal Fibrosis.
Arthritis Research: Methods and Protocols, 91-98.
Avouac, J., Elhai, M., Allanore, Y., 2013. Experimental
models of dermal fibrosis and systemic sclerosis. Joint
Bone Spine, 80 (1), 23-28.
Bataller, R., Brenner, D. A., 2005. Liver fibrosis. Journal
of clinical investigation,115 (2), 209-218.
Clements, P. J., Clements, P.J., Hurwitz, E.L., Wong, W.
K., Seibold, J.R, Mayes, M., White, B., Wigley, F.,
Weisman, M., Walter Barr, W., Larry Moreland, L.,
Medsger, Jr.Th.A., Steen, V.D., Martin, R.W., Collier,
D., Weinstein, A., Lally, E., Varga, J., Weiner, S.R.,
Andrews, B., Abeles, M., Furst, D.E., 2000. Skin
thickness score as a predictor and correlate of outcome
in systemic sclerosis: high‐dose versus low‐dose
penicillamine trial. Arthritis & Rheumatism, 43 (11),
2445-2454.
Driskell, R.R., Lichtenberger, B.M.,
Hoste, E.,
Kretzschmar, K., Simons, B.D., Charalambous, M,
Ferron, S.R., Herault, Y, Pavlovic, G, Ferguson-Smith,
A.C.,
and Watt F.M., 2013. Distinct fibroblast lineages
determine dermal architecture in skin development and
repair. Nature, 504 (7479), 277-281.
Darby, I. A., Hewitson, T. D, 2016. Hypoxia in tissue
repair and fibrosis. Cell and tissue research, 365 (3),
553-562.
Iredale, J. P., 2007. Models of liver fibrosis: exploring the
dynamic nature of inflammation and repair in a solid
organ. Journal of clinical investigation, 117 (3), 539-
548.
Franco, W., Gutierrez-Herrera, E., Kollias, N., Doukas,
A., 2016. Review of applications of fluorescence
excitation to spectroscopy dermatology. British
Journal of Dermatology, 174 (3), 499-504.
Gabrielli, A., Avvedimento, E. V., Krieg, T., 2009.
Scleroderma. New England Journal of Medicine, 360
(19), 1989-2003.
Hinz, B.,, Phan, S.H., Thannickal, V.J., Prunotto, M.,
Desmoulière, A., Varga, J., De Wever, O., Mareel, M.,
Gabbiani, G. 2012. Recent developments in
myofibroblast biology: paradigms for connective
tissue remodelling. The American journal of
pathology, 180.(4),.1340-1355.
Ho,Y.Y., Lagares, D., Tager, A.M., Kapoor, M., 2014.
Fibrosis - a lethal component of systemic sclerosis.
Nature Reviews Rheumatology, 10 (7), 390-402.
Jinnin M., 2010. Mechanisms of skin fibrosis in systemic
sclerosis. The Journal of dermatology, 37 (1), 11-25.
Kang,T., Abignano,
G., Lettieri,
G., Wakefield,
R.J.,
Emery, P., and Del Galdo, F., 2104. Skin imaging in
systemic sclerosis. European journal of rheumatology,
1 (3), 111-116.
Khanna, D., Denton, C. P., 2010. Evidence-based
management of rapidly progressing systemic sclerosis.
Best practice & research Clinical rheumatology, 24
(3), 387-400.
BIODEVICES 2018 - 11th International Conference on Biomedical Electronics and Devices
198